Hepatic lipid accumulation: Cause and consequence of dysregulated glucoregulatory hormones

Journal of Endocrinology

Volumn 234, Issue 1, 2017, Pages R1-R21

  Geisler, Caroline E ^a   Renquist, Benjamin J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Insulin resistance; Nonalcoholic fatty liver disease; Obesity; Peroxisome proliferatoractivated receptor

Indexed keywords

FATTY ACID; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VERY LOW DENSITY LIPOPROTEIN; GLUCAGON; GLUCOSE; HORMONE; HYDROCORTISONE;

ADIPOSE TISSUE; BIOACCUMULATION; DE NOVO LIPOGENESIS; DYSREGULATED GLUCOREGULATORY HORMONE; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; KETOGENESIS; LIPID LIVER LEVEL; LIPID OXIDATION; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER CELL; LIVER FUNCTION; LIVER METABOLISM; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; DIET; ENDOCRINE DISEASE; GLUCONEOGENESIS; HOMEOSTASIS; HYPERINSULINISM; LIPID METABOLISM; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OVERNUTRITION; OXIDATION REDUCTION REACTION; PHYSIOLOGY; VIRUS INFECTION;

ADIPOSE TISSUE; ANIMALS; DIET; ENDOCRINE SYSTEM DISEASES; FATTY LIVER; GLUCAGON; GLUCONEOGENESIS; GLUCOSE; HOMEOSTASIS; HORMONES; HUMANS; HYDROCORTISONE; HYPERINSULINISM; LIPID METABOLISM; LIPIDS; LIPOGENESIS; LIPOLYSIS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OVERNUTRITION; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 85023201036     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-16-0513     Document Type: Review

References (269)

1. Abu-Elheiga L, Brinkley WR, Zhong L, Chirala SS, Woldegiorgis G & Wakil SJ. 2000. The subcellular localization of acetyl-CoA carboxylase 2. PNAS 97:1444-1449. (doi:10.1073/pnas.97.4.1444)
2. Abu-Elheiga L, Oh W, Kordari P & Wakil SJ. 2003. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. PNAS 100:10207-10212. (doi:10.1073/pnas.1733877100)
3. Ahmed A, Rabbitt E, Brady T, Brown C, Guest P, Bujalska IJ, Doig C, Newsome PN, Hubscher S, Elias E, et al. 2012. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One 7:e29531. (doi:10.1371/journal.pone.0029531)
4. Ahn J, Lee H, Chung CH & Ha T. 2011. High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. Biochemical and Biophysical Research Communications 414:664-669. (doi:10.1016/j.bbrc.2011.09.120)
5. Akinci B, Koseoglu FD, Onay H, Yavuz S, Altay C, Simsir IY, Ozisik S, Demir L, Korkut M, Yilmaz N, et al. 2015. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism 64:1086-1095. (doi:10.1016/j.metabol.2015.06.004)
6. Amako Y, Munakata T, Kohara M, Siddiqui A, Peers C & Harris M. 2015. Hepatitis C virus attenuates mitochondrial lipid beta-oxidation by downregulating mitochondrial trifunctional-protein expression. Journal of Virology 89:4092-4101. (doi:10.1128/JVI.01653-14)
7. Amaro A, Fabbrini E, Kars M, Yue P, Schechtman K, Schonfeld G & Klein S. 2010. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 139:149-153. (doi:10.1053/j.gastro.2010.03.039)
8. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, Koves TR, Stevens R, Millington D & Newgard CB. 2004. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nature Medicine 10:268-274. (doi:10.1038/nm995)
9. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T & Gonzalez FJ. 1998. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). Journal of Biological Chemistry 273:5678-5684. (doi:10.1074/jbc.273.10.5678)
10. Armstrong MJ, Hazlehurst JM, Hull D, Guo K, Borrows S, Yu J, Gough SC, Newsome PN & Tomlinson JW. 2014. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes, Obesity and Metabolism 16:651-660. (doi:10.1111/dom.12272)
11. Atshaves BP, Martin GG, Hostetler HA, McIntosh AL, Kier AB & Schroeder F. 2010. Liver fatty acid-binding protein and obesity. Journal of Nutritional Biochemistry 21:1015-1032. (doi:10.1016/j.jnutbio.2010.01.005)
12. Auer MK, Stalla GK & Stieg MR. 2016. Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. Pituitary 19:461-471. (doi:10.1007/s11102-016-0726-1)
13. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS & Maratos-Flier E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 5:426-437. (doi:10.1016/j.cmet.2007.05.002)
14. Bandsma RH, Van Dijk TH, Harmsel At A, Kok T, Reijngoud DJ, Staels B & Kuipers F. 2004. Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast. Journal of Biological Chemistry 279:8930-8937. (doi:10.1074/jbc.M310067200)
15. Barbosa-da-Silva S, Souza-Mello V, Magliano DC, Marinho Tde S, Aguila MB & Mandarim-de-Lacerda CA. 2015. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice. Life Sciences 127:73-81. (doi:10.1016/j.lfs.2015.02.003)
16. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G & Bellentani S. 2005. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44-52. (doi:10.1002/hep.20734)
17. Berglund ED, Kang L, Lee-Young RS, Hasenour CM, Lustig DG, Lynes SE, Donahue EP, Swift LL, Charron MJ & Wasserman DH. 2010. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo. American Journal of Physiology: Endocrinology and Metabolism 299:E607-E614. (doi:10.1152/ajpendo.00263.2010)
18. Berglund ED, Lee-Young RS, Lustig DG, Lynes SE, Donahue EP, Camacho RC, Meredith ME, Magnuson MA, Charron MJ & Wasserman DH. 2009. Hepatic energy state is regulated by glucagon receptor signaling in mice. Journal of Clinical Investigation 119:2412-2422. (doi:10.1172/JCI38650)
19. Bernal-Mizrachi C, Xiaozhong L, Yin L, Knutsen RH, Howard MJ, Arends JJ, Desantis P, Coleman T & Semenkovich CF. 2007. An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoidinduced insulin resistance and hypertension. Cell Metabolism 5:91-102. (doi:10.1016/j.cmet.2006.12.010)
20. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH & Beglinger C. 2014. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 9:e87488. (doi:10.1371/journal.pone.0087488)
21. Bhatia H, Pattnaik BR & Datta M. 2016. Inhibition of mitochondrial beta-oxidation by miR-107 promotes hepatic lipid accumulation and impairs glucose tolerance in vivo. International Journal of Obesity 40:861-869. (doi:10.1038/ijo.2015.225)
22. Bi L, Jiang Z & Zhou J. 2015. The role of lipin-1 in the pathogenesis of alcoholic fatty liver. Alcohol and Alcoholism 50:146-151. (doi:10.1093/alcalc/agu102)
23. Bjornsson OG, Sparks JD, Sparks CE & Gibbons GF. 1994. Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases. European Journal of Clinical Investigation 24:137-148. (doi:10.1111/j.1365-2362.1994.tb00979.x)
24. Blaak EE. 2003. Fatty acid metabolism in obesity and type 2 diabetes mellitus. Proceedings of the Nutrition Society 62:753-760. (doi:10.1079/PNS2003290)
25. Blaak EE, Wagenmakers AJ, Glatz JF, Wolffenbuttel BH, Kemerink GJ, Langenberg CJ, Heidendal GA & Saris WH. 2000. Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. American Journal of Physiology: Endocrinology and Metabolism 279:E146-E154
26. Brand CL, Jorgensen PN, Svendsen I & Holst JJ. 1996. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076-1083. (doi:10.2337/diab.45.8.1076)
27. Browning JD, Baxter J, Satapati S & Burgess SC. 2012. The effect of shortterm fasting on liver and skeletal muscle lipid, glucose, and energy metabolism in healthy women and men. Journal of Lipid Research 53:577-586. (doi:10.1194/jlr.P020867)
28. Busetto L, Digito M, Dalla Monta P, Carraro R & Enzi G. 1993. Omental and epigastric adipose tissue lipolytic activity in human obesity. Effect of abdominal fat distribution and relationship with hyperinsulinemia. Hormone and Metabolic Research 25:365-371. (doi:10.1055/s-2007-1002121)
29. Candia R, Riquelme A, Baudrand R, Carvajal CA, Morales M, Solis N, Pizarro M, Escalona A, Carrasco G, Boza C, et al. 2012. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver International 32:392-399
30. Cha DR, Han JY, Su DM, Zhang Y, Fan X, Breyer MD & Guan Y. 2007. Peroxisome proliferator-activated receptor-alpha deficiency protects aged mice from insulin resistance induced by high-fat diet. American Journal of Nephrology 27:479-482. (doi:10.1159/000106485)
31. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, et al. 1999. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. Journal of Biological Chemistry 274:5692-5700. (doi:10.1074/jbc.274.9.5692)
32. Chen HC, Stone SJ, Zhou P, Buhman KK & Farese RV Jr. 2002. Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue. Diabetes 51:3189-3195. (doi:10.2337/diabetes.51.11.3189)
33. Chirieac DV, Cianci J, Collins HL, Sparks JD & Sparks CE. 2002. Insulin suppression of VLDL apo B secretion is not mediated by the LDL receptor. Biochemical and Biophysical Research Communications 297:134-137. (doi:10.1016/S0006-291X(02)02140-X)
34. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, et al. 2002. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379. (doi:10.1053/jhep.2002.30692)
35. Chon YE, Kim KJ, Jung KS, Kim SU, Park JY, Kimdo Y, Ahn SH, Chon CY, Chung JB, Park KH, et al. 2016. The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. Yonsei Medical Journal 57:885-892. (doi:10.3349/ymj.2016.57.4.885)
36. Chow JC, Planck-Meyer C & Jesse BW. 1990. Gluconeogenic dependence on ketogenesis in isolated sheep hepatocytes. Journal of Dairy Science 73:683-689. (doi:10.3168/jds.S0022-0302(90)78720-6)
37. Clugston RD, Yuen JJ, Hu Y, Abumrad NA, Berk PD, Goldberg IJ, Blaner WS & Huang LS. 2014. CD36-deficient mice are resistant to alcoholand high-carbohydrate-induced hepatic steatosis. Journal of Lipid Research 55:239-246. (doi:10.1194/jlr.M041863)
38. Consoli A. 1992. Role of liver in pathophysiology of NIDDM. Diabetes Care 15:430-441. (doi:10.2337/diacare.15.3.430)
39. Cordoba-Chacon J, Majumdar N, List EO, Diaz-Ruiz A, Frank SJ, Manzano A, Bartrons R, Puchowicz M, Kopchick JJ & Kineman RD. 2015. Growth hormone inhibits hepatic de novo lipogenesis in adult mice. Diabetes 64:3093-3103. (doi:10.2337/db15-0370)
40. Cyphert HA, Alonge KM, Ippagunta SM & Hillgartner FB. 2014. Glucagon stimulates hepatic FGF21 secretion through a PKA-and EPACdependent posttranscriptional mechanism. PLoS One 9:e94996. (doi:10.1371/journal.pone.0094996)
41. Darkhal P, Gao M, Ma Y & Liu D. 2015. Blocking high-fat diet-induced obesity, insulin resistance and fatty liver by overexpression of Il-13 gene in mice. International Journal of Obesity 39:1292-1299. (doi:10.1038/ijo.2015.52)
42. de Guia RM, Rose AJ, Sommerfeld A, Seibert O, Strzoda D, Zota A, Feuchter Y, Krones-Herzig A, Sijmonsma T, Kirilov M, et al. 2015. microRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis. EMBO Journal 34:344-360. (doi:10.15252/embj.201490464)
43. Della Corte C, Fintini D, Giordano U, Cappa M, Brufani C, Majo F, Mennini C & Nobili V. 2013. Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology. Clinical Endocrinology 79:49-54. (doi:10.1111/j.1365-2265.2012.04498.x)
44. Deng X, Zhang W, I OS, Williams JB, Dong Q, Park EA, Raghow R, Unterman TG & Elam MB. 2012. FoxO1 inhibits sterol regulatory element-binding protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. Journal of Biological Chemistry 287:20132-20143. (doi:10.1074/jbc.M112.347211)
45. Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Moller N & Schmitz O. 2004. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. American Journal of Physiology: Endocrinology and Metabolism 286:E488-494. (doi:10.1152/ajpendo.00199.2003)
46. D'Souza AM, Beaudry JL, Szigiato AA, Trumble SJ, Snook LA, Bonen A, Giacca A & Riddell MC. 2012. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. American Journal of Physiology: Gastrointestinal and Liver Physiology 302:G850-G863. (doi:10.1152/ajpgi.00378.2011)
47. Du ZY, Ma T, Liaset B, Keenan AH, Araujo P, Lock EJ, Demizieux L, Degrace P, Froyland L, Kristiansen K, et al. 2013. Dietary eicosapentaenoic acid supplementation accentuates hepatic triglyceride accumulation in mice with impaired fatty acid oxidation capacity. Biochimica et Biophysica Acta 1831:291-299. (doi:10.1016/j.bbalip.2012.10.002)
48. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML & Maratos-Flier E. 2010. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456-463. (doi:10.1053/j.gastro.2010.04.054)
49. Dyck JR, Berthiaume LG, Thomas PD, Kantor PF, Barr AJ, Barr R, Singh D, Hopkins TA, Voilley N, Prentki M, et al. 2000. Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism. Biochemical Journal 350:599-608. (doi:10.1042/bj3500599)
50. Eissing L, Scherer T, Todter K, Knippschild U, Greve JW, Buurman WA, Pinnschmidt HO, Rensen SS, Wolf AM, Bartelt A, et al. 2013. De novo lipogenesis in human fat and liver is linked to ChREBPbeta and metabolic health. Nature Communications 4:1528. (doi:10.1038/ncomms2537)
51. Elam MB, Wilcox HG, Solomon SS & Heimberg M. 1992. In vivo growth hormone treatment stimulates secretion of very low density lipoprotein by the isolated perfused rat liver. Endocrinology 131:2717-2722. (doi:10.1210/endo.131.6.1446613)
52. Elholm M, Dam I, Jorgensen C, Krogsdam AM, Holst D, Kratchmarova I, Gottlicher M, Gustafsson JA, Berge R, Flatmark T, et al. 2001. Acyl-CoA esters antagonize the effects of ligands on peroxisome proliferatoractivated receptor alpha conformation, DNA binding, and interaction with Co-factors. Journal of Biological Chemistry 276:21410-21416. (doi:10.1074/jbc.M101073200)
53. Elias N, Patterson BW & Schonfeld G. 1999. Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology 19:2714-2721. (doi:10.1161/01.ATV.19.11.2714)
54. Ellinghaus P, Wolfrum C, Assmann G, Spener F & Seedorf U. 1999. Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/sterol carrier protein x-deficient mice. Journal of Biological Chemistry 274:2766-2772. (doi:10.1074/jbc.274.5.2766)
55. Ercin CN, Dogru T, Genc H, Celebi G, Aslan F, Gurel H, Kara M, Sertoglu E, Tapan S, Bagci S, et al. 2015. Insulin resistance but not visceral adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease. Metabolic Syndrome and Related Disorders 13:319-325. (doi:10.1089/met.2015.0018)
56. Fabbrini E, Sullivan S & Klein S. 2010. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679-689. (doi:10.1002/hep.23280)
57. Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, Lee H, Catana C, Klibanski A, Patwari P, et al. 2015. FGF21 and the late adaptive response to starvation in humans. Journal of Clinical Investigation 125:4601-4611. (doi:10.1172/JCI83349)
58. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC Jr & Kelly DP. 2006. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metabolism 4:199-210. (doi:10.1016/j.cmet.2006.08.005)
59. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS & Maratos-Flier E. 2010. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781-2789. (doi:10.2337/db10-0193)
60. Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, Kharitonenkov A, Schuppan D, Flier JS & Maratos-Flier E. 2014. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147:1073-1083 e1076. (doi:10.1053/j.gastro.2014.07.044)
61. Foghsgaard S, Andreasen C, Vedtofte L, Andersen ES, Bahne E, Strandberg C, Buhl T, Holst JJ, Svare JA, Clausen TD, et al. 2016. Nonalcoholic fatty liver disease is prevalent in women with prior gestational diabetes mellitus and independently associated with insulin resistance and waist circumference. Diabetes Care 40:109-116 (doi:10.2337/dc16-1017)
62. Franckhauser S, Munoz S, Pujol A, Casellas A, Riu E, Otaegui P, Su B & Bosch F. 2002. Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance. Diabetes 51:624-630. (doi:10.2337/diabetes.51.3.624)
63. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, et al. 2009. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 50:772-780. (doi:10.1002/hep.23094)
64. Gathercole LL, Morgan SA, Bujalska IJ, Hauton D, Stewart PM & Tomlinson JW. 2011. Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One 6:e26223. (doi:10.1371/journal.pone.0026223)
65. Geelen MJ, Beynen AC, Christiansen RZ, Lepreau-Jose MJ & Gibson DM. 1978. Short-term effects of insulin and glucagon on lipid synthesis in isolated rat hepatocyte. Covariance of acetyl-CoA carboxylase activity and the rate of 3H2O incorporation into fatty acids. FEBS Letters 95:326-330. (doi:10.1016/0014-5793(78)81022-9)
66. Geisler CE, Hepler C, Higgins MR & Renquist BJ. 2016. Hepatic adaptations to maintain metabolic homeostasis in response to fasting and refeeding in mice. Nutrition and Metabolism 13:article 62. (doi:10.1186/s12986-016-0122-x)
67. Giralt M, Diaz-Delfin J, Gallego-Escuredo JM, Villarroya J, Domingo P & Villarroya F. 2010. Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment. Current Pharmaceutical Design 16:3371-3378. (doi:10.2174/138161210793563527)
68. Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel AL, Houssier M, Roussel B, Besse-Patin A, Combes M, et al. 2013. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biology 11:e1001485. (doi:10.1371/journal.pbio.1001485)
69. Gonzalez-Manchon C, Martin-Requero A, Ayuso MS & Parrilla R. 1992. Role of endogenous fatty acids in the control of hepatic gluconeogenesis. Archives of Biochemistry and Biophysics 292:95-101. (doi:10.1016/0003-9861(92)90055-2)
70. Goossens GH, Moors CC, Jocken JW, van der Zijl NJ, Jans A, Konings E, Diamant M & Blaak EE. 2016. Altered skeletal muscle fatty acid handling in subjects with impaired glucose tolerance as compared to impaired fasting glucose. Nutrients 8:164. (doi:10.3390/nu8030164)
71. Goulbourne CN & Vaux DJ. 2010. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy? Biochemical Society Transactions 38 292-296. (doi:10.1042/BST0380292)
72. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL & Mancia G. 2005. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48:1359-1365. (doi:10.1007/s00125-005-1798-z)
73. Grimsrud PA, Carson JJ, Hebert AS, Hubler SL, Niemi NM, Bailey DJ, Jochem A, Stapleton DS, Keller MP, Westphall MS, et al. 2012. A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metabolism 16:672-683. (doi:10.1016/j.cmet.2012.10.004)
74. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G & Staels B. 2001. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50:2809-2814. (doi:10.2337/diabetes.50.12.2809)
75. Guo Y, Darshi M, Ma Y, Perkins GA, Shen Z, Haushalter KJ, Saito R, Chen A, Lee YS, Patel HH, et al. 2013. Quantitative proteomic and functional analysis of liver mitochondria from high fat diet (HFD) diabetic mice. Molecular & Cellular Proteomics 12:3744-3758. (doi:10.1074/mcp.m113.027441)
76. Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, Hirschey M, Vaitheesvaran B, Farese RV, Jr., Kurland IJ, et al. 2012. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metabolism 15:873-884. (doi:10.1016/j.cmet.2012.05.002)
77. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, et al. 2006. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312:734-737. (doi:10.1126/science.1123965)
78. Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, Chiu KP, Pettersson S, Wei CL, Ruan Y, et al. 2009. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One 4:e4907. (doi:10.1371/journal.pone.0004907)
79. Hanssen MJ, Wierts R, Hoeks J, Gemmink A, Brans B, Mottaghy FM, Schrauwen P & van Marken Lichtenbelt WD. 2015. Glucose uptake in human brown adipose tissue is impaired upon fasting-induced insulin resistance. Diabetologia 58:586-595. (doi:10.1007/s00125-014-3465-8)
80. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK & Rao MS. 2000. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. Journal of Biological Chemistry 275:28918-28928. (doi:10.1074/jbc.M910350199)
81. Hasni Ebou M, Singh-Estivalet A, Launay JM, Callebert J, Tronche F, Ferre P, Gautier JF, Guillemain G, Breant B, Blondeau B, et al. 2016. Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells. PLoS One 11:e0149343. (doi:10.1371/journal.pone.0149343)
82. Hazlehurst JM & Tomlinson JW. 2013. Non-alcoholic fatty liver disease in common endocrine disorders. European Journal of Endocrinology 169:R27-R37. (doi:10.1530/EJE-13-0296)
83. Hegardt FG. 1999. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochemical Journal 338:569-582. (doi:10.1042/bj3380569)
84. Hoeks J, van Herpen NA, Mensink M, Moonen-Kornips E, van Beurden D, Hesselink MK & Schrauwen P. 2010. Prolonged fasting identifies skeletal muscle mitochondrial dysfunction as consequence rather than cause of human insulin resistance. Diabetes 59:2117-2125. (doi:10.2337/db10-0519)
85. Hoffstedt J, Wahrenberg H, Thorne A & Lonnqvist F. 1996. The metabolic syndrome is related to beta 3-adrenoceptor sensitivity in visceral adipose tissue. Diabetologia 39:838-844. (doi:10.1007/s001250050518)
86. Howe HR 3rd, Heidal K, Choi MD, Kraus RM, Boyle K & Hickner RC. 2011. Increased adipose tissue lipolysis after a 2-week high-fat diet in sedentary overweight/obese men. Metabolism 60:976-981. (doi:10.1016/j.metabol.2010.09.007)
87. Hu M, Wang F, Li X, Rogers CQ, Liang X, Finck BN, Mitra MS, Zhang R, Mitchell DA & You M. 2012. Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. Hepatology 55:437-446. (doi:10.1002/hep.24708)
88. Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, Wagner JD, Matern D, Rinaldo P & Cline JM. 2005. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 128:1381-1390. (doi:10.1053/j.gastro.2005.02.001)
89. Ide T, Tsunoda M, Mochizuki T & Murakami K. 2004. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice. Medical Science Monitor 10:BR388-BR395
90. Ido-Kitamura Y, Sasaki T, Kobayashi M, Kim HJ, Lee YS, Kikuchi O, Yokota-Hashimoto H, Iizuka K, Accili D & Kitamura T. 2012. Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of Chrebp O-glycosylation. PLoS One 7:e47231. (doi:10.1371/journal.pone.0047231)
91. Iizuka K, Bruick RK, Liang G, Horton JD & Uyeda K. 2004. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. PNAS 101:7281-7286. (doi:10.1073/pnas.0401516101)
92. Im SS, Kim MY, Kwon SK, Kim TH, Bae JS, Kim H, Kim KS, Oh GT & Ahn YH. 2011. Peroxisome proliferator-activated receptor (alpha) is responsible for the up-regulation of hepatic glucose-6-phosphatase gene expression in fasting and db/db Mice. Journal of Biological Chemistry 286:1157-1164. (doi:10.1074/jbc.M110.157875)
93. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R & Leclercq I. 2003. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38:123-132. (doi:10.1053/jhep.2003.50307)
94. Izumida Y, Yahagi N, Takeuchi Y, Nishi M, Shikama A, Takarada A, Masuda Y, Kubota M, Matsuzaka T, Nakagawa Y, et al. 2013. Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization. Nature Communications 4:2316
95. Janssens S, Jonkers RA, Groen AK, Nicolay K, van Loon LJ & Prompers JJ. 2015. Effects of acute exercise on lipid content and dietary lipid uptake in liver and skeletal muscle of lean and diabetic rats. American Journal of Physiology: Endocrinology and Metabolism 309:E874-E883
96. Jensen MD, Haymond MW, Rizza RA, Cryer PE & Miles JM. 1989. Influence of body fat distribution on free fatty acid metabolism in obesity. Journal of Clinical Investigation 83:1168-1173. (doi:10.1172/JCI113997)
97. Jeon SM, Chandel NS & Hay N. 2012. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485:661-665. (doi:10.1038/nature11066)
98. Jocken JW, Langin D, Smit E, Saris WH, Valle C, Hul GB, Holm C, Arner P & Blaak EE. 2007. Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. Journal of Clinical Endocrinology and Metabolism 92:2292-2299. (doi:10.1210/jc.2006-1318)
99. Jonkers RA, van Loon LJ, Nicolay K & Prompers JJ. 2013. In vivo postprandial lipid partitioning in liver and skeletal muscle in prediabetic and diabetic rats. Diabetologia 56:618-626. (doi:10.1007/s00125-012-2792-x)
100. Junker AE, Gluud L, Holst JJ, Knop FK & Vilsboll T. 2016. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. Journal of Internal Medicine 279:485-493. (doi:10.1111/joim.12462)
101. Katz J & Tayek JA. 1998. Gluconeogenesis and the Cori cycle in 12-, 20-, and 40-h-fasted humans. American Journal of Physiology 275:E537-E542
102. Kelley DE & Simoneau JA. 1994. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation 94:2349-2356. (doi:10.1172/JCI117600)
103. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, Wu MS, Meurer R, Forrest MJ, Conner MW, et al. 1998. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 139:4920-4927. (doi:10.1210/endo.139.12.6384)
104. Kennedy AR, Pissios P, Otu H, Roberson R, Xue B, Asakura K, Furukawa N, Marino FE, Liu FF, Kahn BB, et al. 2007. A high-fat, ketogenic diet induces a unique metabolic state in mice. American Journal of Physiology: Endocrinology and Metabolism 292:E1724-1739. (doi:10.1152/ajpendo.00717.2006)
105. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B & Wahli W. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. Journal of Clinical Investigation 103:1489-1498. (doi:10.1172/JCI6223)
106. Kharbanda KK, Todero SL, Ward BW, Cannella JJ, 3rd & Tuma DJ. 2009. Betaine administration corrects ethanol-induced defective VLDL secretion. Molecular and Cellular Biochemistry 327:75-78. (doi:10.1007/s11010-009-0044-2)
107. Kim DH, Zhang T, Lee S, Calabuig-Navarro V, Yamauchi J, Piccirillo A, Fan Y, Uppala R, Goetzman E & Dong HH. 2014. FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver. Endocrinology 155:1255-1267. (doi:10.1210/en.2013-1856)
108. Kim HJ, Kim JH, Choe WH, Kwon SY & Lee CH. 2014. Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study. Clinical and Molecular Hepatology 20:154-161. (doi:10.3350/cmh.2014.20.2.154)
109. Kim S, Sohn I, Ahn JI, Lee KH, Lee YS & Lee YS. 2004. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 340:99-109. (doi:10.1016/j.gene.2004.06.015)
110. Kineman RD, Majumdar N, Subbaiah PV & Cordoba-Chacon J. 2016. Hepatic PPARgamma is not essential for the rapid development of steatosis after loss of hepatic GH Signaling, in adult male mice. Endocrinology 157:1728-1735. (doi:10.1210/en.2015-2077)
111. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, et al. 2007. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. International Journal of Molecular Medicine 20:351-358
112. Koliaki C & Roden M. 2013. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Molecular and Cellular Endocrinology 379:35-42. (doi:10.1016/j.mce.2013.06.002)
113. Koo HY, Miyashita M, Cho BH & Nakamura MT. 2009. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochemical and Biophysical Research Communications 390:285-289. (doi:10.1016/j.bbrc.2009.09.109)
114. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, et al. 1997. 11beta-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. PNAS 94:14924-14929. (doi:10.1073/pnas.94.26.14924)
115. Kotronen A, Yki-Jarvinen H, Mannisto S, Saarikoski L, Korpi-Hyovalti E, Oksa H, Saltevo J, Saaristo T, Sundvall J, Tuomilehto J, et al. 2010. Non-alcoholic and alcoholic fatty liver disease-two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health 10:237. (doi:10.1186/1471-2458-10-237)
116. Krausz Y, Bar-On H & Shafrir E. 1981. Origin and pattern of glucocorticoidinduced hyperlipidemia in rats. Dose-dependent bimodal changes in serum lipids and lipoproteins in relation to hepatic lipogenesis and tissue lipoprotein lipase activity. Biochimica et Biophysica Acta 663:69-82. (doi:10.1016/0005-2760(81)90195-8)
117. Kumar NS, Shashibhushan J, Malappa, Venugopal K, Vishwanatha H & Menon M. 2015. Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART). Journal of Clinical and Diagnostic Research 9:OC05-08
118. Kyriazis GA, Soundarapandian MM & Tyrberg B. 2012. Sweet taste receptor signaling in beta cells mediates fructose-induced potentiation of glucose-stimulated insulin secretion. PNAS 109:E524-E532. (doi:10.1073/pnas.1115183109)
119. Lacasa D, Agli B & Giudicelli Y. 1988. Permissive action of glucocorticoids on catecholamine-induced lipolysis: direct 'in vitro' effects on the fat cell beta-adrenoreceptor-coupled-adenylate cyclase system. Biochemical and Biophysical Research Communications 153:489-497. (doi:10.1016/S0006-291X(88)81121-5)
120. Lambert JE, Ramos-Roman MA, Browning JD & Parks EJ. 2014. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146:726-735. (doi:10.1053/j.gastro.2013.11.049)
121. Lamberts SW, Timmermans HA, Kramer-Blankestijn M & Birkenhager JC. 1975. The mechanism of the potentiating effect of glucocorticoids on catecholamine-induced lipolysis. Metabolism 24:681-689. (doi:10.1016/0026-0495(75)90035-9)
122. Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, Ryden M, Arner E, Sicard A, Jenkins CM, Viguerie N, et al. 2005. Adipocyte lipases and defect of lipolysis in human obesity. Diabetes 54:3190-3197. (doi:10.2337/diabetes.54.11.3190)
123. Large V, Arner P, Reynisdottir S, Grober J, Van Harmelen V, Holm C & Langin D. 1998. Hormone-sensitive lipase expression and activity in relation to lipolysis in human fat cells. Journal of Lipid Research 39:1688-1695
124. Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K & Farrell GC. 2012. Peroxisome proliferator-activated receptor-alpha agonist, Wy 14, 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 27:341-350. (doi:10.1111/j.1440-1746.2011.06939.x)
125. Le Marchand SJ & Piston DW. 2010. Glucose suppression of glucagon secretion: metabolic and calcium responses from alpha-cells in intact mouse pancreatic islets. Journal of Biological Chemistry 285:14389-14398. (doi:10.1074/jbc.M109.069195)
126. Le May C, Pineau T, Bigot K, Kohl C, Girard J & Pegorier JP. 2000. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Letter 475:163-166. (doi:10.1016/S0014-5793(00)01648-3)
127. Lee GY, Kim NH, Zhao ZS, Cha BS & Kim YS. 2004. Peroxisomalproliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochemical Journal 378:983-990. (doi:10.1042/bj20031565)
128. Lee Y, Wang MY, Du XQ, Charron MJ & Unger RH. 2011. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391-397. (doi:10.2337/db10-0426)
129. Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W & Auwerx J. 1996. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. Journal of Biological Chemistry 271:1764-1769. (doi:10.1074/jbc.271.3.1764)
130. Lemke U, Krones-Herzig A, Berriel Diaz M, Narvekar P, Ziegler A, Vegiopoulos A, Cato AC, Bohl S, Klingmuller U, Screaton RA, et al. 2008. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metabolism 8:212-223. (doi:10.1016/j.cmet.2008.08.001)
131. Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J & Serfaty L. 2006. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulinresistant lipodystrophic HIV-infected patients. AIDS 20:387-395. (doi:10.1097/01.aids.0000206503.01536.11)
132. Leone TC, Weinheimer CJ & Kelly DP. 1999. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. PNAS 96:7473-7478. (doi:10.1073/pnas.96.13.7473)
133. Lewis GF, Carpentier A, Adeli K & Giacca A. 2002. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 23:201-229. (doi:10.1210/edrv.23.2.0461)
134. Li G, Hernandez-Ono A, Crooke RM, Graham MJ & Ginsberg HN. 2011. Effects of antisense-mediated inhibition of 11beta-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. Journal of Lipid Research 52:971-981. (doi:10.1194/jlr.M013748)
135. Li HH, Tyburski JB, Wang YW, Strawn S, Moon BH, Kallakury BV, Gonzalez FJ & Fornace AJ, Jr. 2014. Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor alpha protects against alcoholic liver disease. Alcoholism Clinical and Experimental Research Journal 38:1520-1531. (doi:10.1111/acer.12424)
136. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N & Loria P. 2006. Hepatic steatosis and insulin resistance: does etiology make a difference? Journal of Hepatology 44 190-196. (doi:10.1016/j.jhep.2005.06.018)
137. Lopez-Soldado I, Zafra D, Duran J, Adrover A, Calbo J & Guinovart JJ. 2015. Liver glycogen reduces food intake and attenuates obesity in a high-fat diet-fed mouse model. Diabetes 64:796-807. (doi:10.2337/db14-0728)
138. Macias J, Gonzalez J, Tural C, Ortega-Gonzalez E, Pulido F, Rubio R, Cifuentes C, Diaz-Menendez M, Jou A, Rubio P, et al. 2014. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 28:1279-1287. (doi:10.1097/QAD.0000000000000248)
139. Manchanayake J, Chitturi S, Nolan C & Farrell GC. 2011. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 26:510-516. (doi:10.1111/j.1440-1746.2010.06528.x)
140. Mandal A, Mukherjee A, Lakshmy R, Kabra SK & Lodha R. 2016. Dyslipidemia in HIV infected children receiving highly active antiretroviral therapy. Indian Journal of Pediatrics 83:226-231. (doi:10.1007/s12098-015-1859-3)
141. Manmontri B, Sariahmetoglu M, Donkor J, Bou Khalil M, Sundaram M, Yao Z, Reue K, Lehner R & Brindley DN. 2008. Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically. Journal of Lipid Research 49:1056-1067. (doi:10.1194/jlr.M800013-JLR200)
142. Mannisto VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, Matte AK, Venesmaa S, Kakela P, Karja V, et al. 2015. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver International 35:1853-1861. (doi:10.1111/liv.12769)
143. Marcelino H, Veyrat-Durebex C, Summermatter S, Sarafian D, Miles-Chan J, Arsenijevic D, Zani F, Montani JP, Seydoux J, Solinas G, et al. 2013. A role for adipose tissue de novo lipogenesis in glucose homeostasis during catch-up growth: a Randle cycle favoring fat storage. Diabetes 62:362-372. (doi:10.2337/db12-0255)
144. Marcus C, Bolme P, Micha-Johansson G, Margery V & Bronnegard M. 1994. Growth hormone increases the lipolytic sensitivity for catecholamines in adipocytes from healthy adults. Life Sciences 54:1335-1341. (doi:10.1016/0024-3205(94)00512-5)
145. Marino L & Jornayvaz FR. 2015. Endocrine causes of nonalcoholic fatty liver disease. World Journal of Gastroenterology 21:11053-11076. (doi:10.3748/wjg.v21.i39.11053)
146. Massillon D, Barzilai N, Hawkins M, Prus-Wertheimer D & Rossetti L. 1997. Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes 46:153-157. (doi:10.2337/diab.46.1.153)
147. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR & Flier JS. 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170. (doi:10.1126/science.1066285)
148. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B, Jr., Reitman ML & Gonzalez FJ. 2003. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. Journal of Clinical Investigation 111:737-747. (doi:10.1172/JCI200317223)
149. Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, Morse CG, Benator D, Kovacs JA & Hadigan C. 2015. Pioglitazone for hepatic steatosis in HIV/Hepatitis C virus coinfection. AIDS Research and Human Retroviruses 31:961-966. (doi:10.1089/aid.2015.0093)
150. Meijssen S, Cabezas MC, Ballieux CG, Derksen RJ, Bilecen S & Erkelens DW. 2001. Insulin mediated inhibition of hormone sensitive lipase activity in vivo in relation to endogenous catecholamines in healthy subjects. Journal of Clinical Endocrinology and Metabolism 86:4193-4197. (doi:10.1210/jcem.86.9.7794)
151. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C & Feingold KR. 2000. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141:4021-4031. (doi:10.1210/endo.141.11.7771)
152. Migliorini RH, Garofalo MA & Kettelhut IC. 1997. Increased sympathetic activity in rat white adipose tissue during prolonged fasting. American Journal of Physiology 272:R656-R661
153. Minehira K, Young SG, Villanueva CJ, Yetukuri L, Oresic M, Hellerstein MK, Farese RV, Jr., Horton JD, Preitner F, Thorens B, et al. 2008. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. Journal of Lipid Research 49:2038-2044. (doi:10.1194/jlr.M800248-JLR200)
154. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla MV, Fernandez-Bermejo M, Lozano-Rodriguez T, Vargas-Castrillon J, Buque X, Ochoa B, Aspichueta P, et al. 2011. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in nonalcoholic steatohepatitis and chronic hepatitis C. Gut 60:1394-1402. (doi:10.1136/gut.2010.222844)
155. Mittendorfer B, Magkos F, Fabbrini E, Mohammed BS & Klein S. 2009. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity 17:1872-1877. (doi:10.1038/oby.2009.224)
156. Montgomery MK, Hallahan NL, Brown SH, Liu M, Mitchell TW, Cooney GJ & Turner N. 2013. Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding. Diabetologia 56:1129-1139. (doi:10.1007/s00125-013-2846-8)
157. Moran-Salvador E, Lopez-Parra M, Garcia-Alonso V, Titos E, Martinez-Clemente M, Gonzalez-Periz A, Lopez-Vicario C, Barak Y, Arroyo V & Claria J. 2011. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophagespecific conditional knockouts. FASEB Journal 25:2538-2550. (doi:10.1096/fj.10-173716)
158. Morillas M, Gomez-Puertas P, Rubi B, Clotet J, Arino J, Valencia A, Hegardt FG, Serra D & Asins G. 2002. Structural model of a malonyl-CoA-binding site of carnitine octanoyltransferase and carnitine palmitoyltransferase I: mutational analysis of a malonyl-CoA affinity domain. Journal of Biological Chemistry 277:11473-11480. (doi:10.1074/jbc.M111628200)
159. Mottillo EP, Balasubramanian P, Lee YH, Weng C, Kershaw EE & Granneman JG. 2014. Coupling of lipolysis and de novo lipogenesis in brown, beige, and white adipose tissues during chronic beta3-adrenergic receptor activation. Journal of Lipid Research 55:2276-2286. (doi:10.1194/jlr.M050005)
160. Muller WA, Faloona GR, Aguilar-Parada E & Unger RH. 1970. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. New England Journal of Medicine 283:109-115. (doi:10.1056/NEJM197007162830301)
161. Muratoglu M, Kuyumjian J & Kalant N. 1986. First-pass hepatic uptake and utilization of glucose in the rat. Biochemical Journal 233:245-248. (doi:10.1042/bj2330245)
162. Nagai Y, Nishio Y, Nakamura T, Maegawa H, Kikkawa R & Kashiwagi A. 2002. Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. American Journal of Physiology: Endocrinology and Metabolism 282:E1180-E1190. (doi:10.1152/ajpendo.00471.2001)
163. Napal L, Marrero PF & Haro D. 2005. An intronic peroxisome proliferatoractivated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A. Journal of Molecular Biology 354:751-759. (doi:10.1016/j.jmb.2005.09.097)
164. Nerurkar PV, Shikuma CM & Nerurkar VR. 2001. Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy. Clinical Biochemistry 34:519-529. (doi:10.1016/S0009-9120(01)00239-9)
165. Nishino N, Tamori Y & Kasuga M. 2007. Insulin efficiently stores triglycerides in adipocytes by inhibiting lipolysis and repressing PGC-1alpha induction. Kobe Journal of Medical Sciences 53:99-106
166. Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y, et al. 2012. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. European Journal of Endocrinology 167:67-74. (doi:10.1530/EJE-12-0252)
167. Nosadini R, Avogaro A, Trevisan R, Duner E, Marescotti C, Iori E, Cobelli C & Toffolo G. 1985. Acetoacetate and 3-hydroxybutyrate kinetics in obese and insulin-dependent diabetic humans. American Journal of Physiology 248:R611-R620
168. O'Sullivan D, van der Windt GJ, Huang SC, Curtis JD, Chang CH, Buck MD, Qiu J, Smith AM, Lam WY, DiPlato LM, et al. 2014. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 41:75-88. (doi:10.1016/j.immuni.2014.06.005)
169. Ottosson M, Vikman-Adolfsson K, Enerback S, Olivecrona G & Bjorntorp P. 1994. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. Journal of Clinical Endocrinology and Metabolism 79:820-825
170. Pacak K, Palkovits M, Kopin IJ & Goldstein DS. 1995. Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: in vivo microdialysis studies. Frontiers in Neuroendocrinology 16:89-150. (doi:10.1006/frne.1995.1004)
171. Pan HJ, Chang HT & Lee CH. 2016. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients. Journal of the Formosan Medical Association 115:411-417. (doi:10.1016/j. jfma.2015.05.006)
172. Pan X, Wang P, Luo J, Wang Z, Song Y, Ye J & Hou X. 2015. Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients. Endocrine 48:834-847. (doi:10.1007/s12020-014-0384-x)
173. Pardina E, Baena-Fustegueras JA, Llamas R, Catalan R, Galard R, Lecube A, Fort JM, Llobera M, Allende H, Vargas V, et al. 2009. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obesity Surgery 19:608-616. (doi:10.1007/s11695-009-9827-5)
174. Patel JN, Coppack SW, Goldstein DS, Miles JM & Eisenhofer G. 2002. Norepinephrine spillover from human adipose tissue before and after a 72-hour fast. Journal of Clinical Endocrinology and Metabolism 87:3373-3377. (doi:10.1210/jcem.87.7.8695)
175. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR & Mullins JJ. 2004. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. PNAS 101:7088-7093. (doi:10.1073/pnas.0305524101)
176. Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, Koenig W, Marz W, Tafuri S, Wahli W, et al. 2004. PPARalpha governs glycerol metabolism. Journal of Clinical Investigation 114:94-103. (doi:10.1172/JCI200420468)
177. Patsouris D, Reddy JK, Muller M & Kersten S. 2006. Peroxisome proliferator-activated receptor alpha mediates the effects of highfat diet on hepatic gene expression. Endocrinology 147:1508-1516. (doi:10.1210/en.2005-1132)
178. Patterson RE, Kalavalapalli S, Williams CM, Nautiyal M, Mathew JT, Martinez J, Reinhard MK, McDougall DJ, Rocca JR, Yost RA, et al. 2016. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. American Journal of Physiology: Endocrinology and Metabolism 310:E484-494. (doi:10.1152/ajpendo.00492.2015)
179. Pawlak M, Bauge E, Lalloyer F, Lefebvre P & Staels B. 2015. Ketone body therapy protects from lipotoxicity and acute liver failure upon pparalpha deficiency. Molecular Endocrinology 29:1134-1143. (doi:10.1210/me.2014-1383)
180. Pettinelli P & Videla LA. 2011. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. Journal of Clinical Endocrinology and Metabolism 96:1424-1430. (doi:10.1210/jc.2010-2129)
181. Pettit FH, Pelley JW & Reed LJ. 1975. Regulation of pyruvate dehydrogenase kinase and phosphatase by acetyl-CoA/CoA and NADH/NAD ratios. Biochemical and Biophysical Research Communications 65:575-582. (doi:10.1016/S0006-291X(75)80185-9)
182. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC & Staels B. 2002. Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Molecular Endocrinology 16:1013-1028
183. Pollitt RJ. 1995. Disorders of mitochondrial long-chain fatty acid oxidation. Journal of Inherited Metabolic Disease 18:473-490. (doi:10.1007/BF00710058)
184. Pratley RE, Coon PJ, Rogus EM & Goldberg AP. 1995. Effects of weight loss on norepinephrine and insulin levels in obese older men. Metabolism 44:438-444. (doi:10.1016/0026-0495(95)90049-7)
185. Quant PA, Tubbs PK & Brand MD. 1990. Glucagon activates mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in vivo by decreasing the extent of succinylation of the enzyme. European Journal of Biochemistry 187:169-174. (doi:10.1111/j.1432-1033.1990.tb15291.x)
186. Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, de Groot PJ, Muller M & Kersten S. 2007. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Research 2007:26839. (doi:10.1155/2007/26839)
187. Rasineni K, Penrice DD, Natarajan SK, McNiven MA, McVicker BL, Kharbanda KK, Casey CA & Harris EN. 2016. Alcoholic vs nonalcoholic fatty liver in rats: distinct differences in endocytosis and vesicle trafficking despite similar pathology. BMC Gastroenterology 16:27. (doi:10.1186/s12876-016-0433-4)
188. Rector RS, Morris EM, Ridenhour S, Meers GM, Hsu FF, Turk J & Ibdah JA. 2013. Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect. Hepatology 57:2213-2223. (doi:10.1002/hep.26285)
189. Rector RS, Payne RM & Ibdah JA. 2008. Mitochondrial trifunctional protein defects: clinical implications and therapeutic approaches. Advanced Drug Delivery Reviews 60:1488-1496. (doi:10.1016/j.addr.2008.04.014)
190. Reed DR, Tordoff MG & Friedman MI. 1991. Enhanced acceptance and metabolism of fats by rats fed a high-fat diet. American Journal of Physiology 261:R1084-R1088
191. Revollo JR, Oakley RH, Lu NZ, Kadmiel M, Gandhavadi M & Cidlowski JA. 2013. HES1 is a master regulator of glucocorticoid receptor-dependent gene expression. Science Signaling 6:ra103. (doi:10.1126/scisignal.2004389)
192. Rochford JJ. 2014. Mouse models of lipodystrophy and their significance in understanding fat regulation. Current Topics in Developmental Biology 109:53-96. (doi:10.1016/b978-0-12-397920-9.00005-6)
193. Rodriguez JC, Gil-Gomez G, Hegardt FG & Haro D. 1994. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. Journal of Biological Chemistry 269:18767-18772
194. Roglans N, Vila L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M & Laguna JC. 2007. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology 45:778-788. (doi:10.1002/hep.21499)
195. Rohrer S, Menge BA, Gruber L, Deacon CF, Schmidt WE, Veldhuis JD, Holst JJ & Meier JJ. 2012. Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals. Journal of Clinical Endocrinology and Metabolism 97:E791-E795. (doi:10.1210/jc.2011-3439)
196. Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Jouness RI, Saponaro C, et al. 2016. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology 63:107-116. (doi:10.1002/hep.28287)
197. Rothman DL, Magnusson I, Katz LD, Shulman RG & Shulman GI. 1991. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 254:573-576. (doi:10.1126/science.1948033)
198. Ruiz-Ramirez A, Chavez-Salgado M, Peneda-Flores JA, Zapata E, Masso F & El-Hafidi M. 2011. High-sucrose diet increases ROS generation, FFA accumulation, UCP2 level, and proton leak in liver mitochondria. American Journal of Physiology: Endocrinology and Metabolism 301:E1198-1207. (doi:10.1152/ajpendo.00631.2010)
199. Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE & Gorden P. 2013. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. Journal of Hepatology 59:131-137. (doi:10.1016/j.jhep.2013.02.007)
200. Saha PK, Kojima H, Martinez-Botas J, Sunehag AL & Chan L. 2004. Metabolic adaptations in the absence of perilipin: increased betaoxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice. Journal of Biological Chemistry 279:35150-35158. (doi:10.1074/jbc.M405499200)
201. Sambandam N, Steinmetz M, Chu A, Altarejos JY, Dyck JR & Lopaschuk GD. 2004. Malonyl-CoA decarboxylase (MCD) is differentially regulated in subcellular compartments by 5'AMPactivated protein kinase (AMPK). Studies using H9c2 cells overexpressing MCD and AMPK by adenoviral gene transfer technique. European Journal of Biochemistry 271:2831-2840. (doi:10.1111/j.1432-1033.2004.04218.x)
202. Samocha-Bonet D, Chisholm DJ, Tonks K, Campbell LV & Greenfield JR. 2012. Insulin-sensitive obesity in humans-a 'favorable fat' phenotype? Trends in Endocrinology and Metabolism 23 116-124. (doi:10.1016/j.tem.2011.12.005)
203. Satapathy SK, Kuwajima V, Nadelson J, Atiq O & Sanyal AJ. 2015. Drug-induced fatty liver disease: An overview of pathogenesis and management. Annals of hepatology 14:789-806. (doi:10.5604/16652681.1171749)
204. Schadinger SE, Bucher NL, Schreiber BM & Farmer SR. 2005. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. American Journal of Physiology: Endocrinology and Metabolism 288:E1195-1205. (doi:10.1152/ajpendo.00513.2004)
205. Schindhelm RK, Heine RJ & Diamant M. 2007. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:e94; author reply e95. (doi:10.2337/dc07-0982)
206. Schultz A, Barbosa-da-Silva S, Aguila MB & Mandarim-de-Lacerda CA. 2015. Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose. Food & Function 6:1684-1691. (doi:10.1039/c5fo00251f)
207. Schultz A, Neil D, Aguila MB & Mandarim-de-Lacerda CA. 2013. Hepatic adverse effects of fructose consumption independent of overweight/obesity. International Journal of Molecular Sciences 14:21873-21886. (doi:10.3390/ijms141121873)
208. Schwarz JM, Linfoot P, Dare D & Aghajanian K. 2003. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. American Journal of Clinical Nutrition 77:43-50
209. Shaw RJ. 2013. Metformin trims fats to restore insulin sensitivity. Nature Medicine 19: 1570-1572. (doi:10.1038/nm.3414)
210. Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB, Li Y, Bunkenborg J, Alt FW, Denu JM, et al. 2010. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metabolism 12:654-661. (doi:10.1016/j.cmet.2010.11.003)
211. Shojaee-Moradie F, Ma Y, Lou S, Hovorka R & Umpleby AM. 2013. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes 62:4063-4069. (doi:10.2337/db13-0935)
212. Siler SQ, Neese RA & Hellerstein MK. 1999. De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. American Journal of Clinical Nutrition 70:928-936
213. Simpson KJ, Venkatesan S, Smith GD & Peters TJ. 1990. Very-lowdensity lipoprotein-triacylglycerol (VLDL-TG) turnover in alcoholic subjects. Biochemical Society Transactions 18: 1189-1191. (doi:10.1042/bst0181189)
214. Softic S, Boucher J, Solheim MH, Fujisaka S, Haering MF, Homan EP, Winnay J, Perez-Atayde AR & Kahn CR. 2016. Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD. Diabetes 65:2187-2200. (doi:10.2337/db16-0213)
215. Solinas G, Summermatter S, Mainieri D, Gubler M, Pirola L, Wymann MP, Rusconi S, Montani JP, Seydoux J & Dulloo AG. 2004. The direct effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between de novo lipogenesis and lipid oxidation. FEBS Letter 577:539-544. (doi:10.1016/j.febslet.2004.10.066)
216. Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, Hori RT, Cook GA & Park EA. 2010. Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Molecular and Cellular Endocrinology 325 54-63. (doi:10.1016/j.mce.2010.05.019)
217. Souza-Mello V. 2015. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World Journal of Hepatology 7:1012-1019. (doi:10.4254/wjh.v7.i8.1012)
218. Stark B & Keller U. 1987. Alpha 1-adrenergic stimulation of ketogenesis and fatty acid oxidation is associated with inhibition of lipogenesis in rat hepatocytes. Experientia 43:1104-1106. (doi:10.1007/bf01956049)
219. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A & Haring HU. 2008. Identification and characterization of metabolically benign obesity in humans. Archives of Internal Medicine 168:1609-1616. (doi:10.1001/archinte.168.15.1609)
220. Stefan N, Ramsauer M, Jordan P, Nowotny B, Kantartzis K, Machann J, Hwang JH, Nowotny P, Kahl S, Harreiter J, et al. 2014. Inhibition of 11beta-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebocontrolled trial. Lancet Diabetes & Endocrinology 2:406-416. (doi:10.1016/s2213-8587(13)70170-0)
221. Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula IJ, Brown NF & O'Doherty RM. 2008. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. American Journal of Physiology: Endocrinology and Metabolism 294:E969-E977. (doi:10.1152/ajpendo.00497.2007)
222. Steffensen C, Pereira AM, Dekkers OM & Jorgensen JO. 2016. DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in Type 2 Diabetes patients: a systematic review and meta-analysis. European Journal of Endocrinology 175:R247-R253. (doi:10.1530/EJE-16-0434)
223. Steneberg P, Sykaras AG, Backlund F, Straseviciene J, Soderstrom I & Edlund H. 2015. Hyperinsulinemia enhances hepatic expression of the fatty acid transporter Cd36 and provokes hepatosteatosis and hepatic insulin resistance. Journal of Biological Chemistry 290:19034-19043. (doi:10.1074/jbc.M115.640292)
224. Sunny NE, Satapati S, Fu X, He T, Mehdibeigi R, Spring-Robinson C, Duarte J, Potthoff MJ, Browning JD & Burgess SC. 2010. Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. American Journal of Physiology: Endocrinology and Metabolism 298:E1226-E1235. (doi:10.1152/ajpendo.00033.2010)
225. Tachibana K, Kobayashi Y, Tanaka T, Tagami M, Sugiyama A, Katayama T, Ueda C, Yamasaki D, Ishimoto K, Sumitomo M, et al. 2005. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nuclear Receptor 3:3. (doi:10.1186/1478-1336-3-3)
226. Takahashi Y, Ohoka N, Hayashi H & Sato R. 2008. TRB3 suppresses adipocyte differentiation by negatively regulating PPARgamma transcriptional activity. Journal of Lipid Research 49:880-892. (doi:10.1194/jlr.M700545-JLR200)
227. Tardif A, Julien N, Pelletier A, Thibault G, Srivastava AK, Chiasson JL & Coderre L. 2001. Chronic exposure to beta-hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes. American Journal of Physiology: Endocrinology and Metabolism 281:E1205-E1212
228. Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L & Falezza G. 2006. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clinical Endocrinology 64:337-341. (doi:10.1111/j.1365-2265.2006.02466.x)
229. Thorp AA & Schlaich MP. 2015. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. Journal of Diabetes Research 2015:341583
230. Toshikuni N, Tsutsumi M & Arisawa T. 2014. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World Journal of Gastroenterology 20:8393-8406. (doi:10.3748/wjg.v20.i26.8393)
231. Turpeinen AK, Takala TO, Nuutila P, Axelin T, Luotolahti M, Haaparanta M, Bergman J, Hamalainen H, Iida H, Maki M, et al. 1999. Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R, S)-[18F]fluoro-6-thia-heptadecanoic acid. Diabetes 48:1245-1250. (doi:10.2337/diabetes.48.6.1245)
232. Tutwiler GF & Dellevigne P. 1979. Action of the oral hypoglycemic agent 2-tetradecylglycidic acid on hepatic fatty acid oxidation and gluconeogenesis. Journal of Biological Chemistry 254:2935-2941
233. Tuyama AC & Chang CY. 2012. Non-alcoholic fatty liver disease. Journal of Diabetes 4:266-280. (doi:10.1111/j.1753-0407.2012.00204.x)
234. Unger RH & Cherrington AD. 2012. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. Journal of Clinical Investigation 122:4-12. (doi:10.1172/JCI60016)
235. Unger RH, Madison LL & Muller WA. 1972. Abnormal alpha cell function in diabetics response to insulin. Diabetes 21:301-307. (doi:10.2337/diab.21.5.301)
236. Valentine RJ, Coughlan KA, Ruderman NB & Saha AK. 2014. Insulin inhibits AMPK activity and phosphorylates AMPK Ser(4)(8)(5)/(4)(9)(1) through Akt in hepatocytes, myotubes and incubated rat skeletal muscle. Archives of Biochemistry and Biophysics 562:62-69. (doi:10.1016/j.abb.2014.08.013)
237. Vallet-Pichard A, Mallet V & Pol S. 2012. Nonalcoholic fatty liver disease and HIV infection. Seminars in Liver Disease 32:158-166. (doi:10.1055/s-0032-1316471)
238. Vega RB, Huss JM & Kelly DP. 2000. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Molecular and Cellular Biology 20:1868-1876. (doi:10.1128/MCB.20.5.1868-1876.2000)
239. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS & Moller DE. 1996. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. Journal of Clinical Investigation 97:2553-2561. (doi:10.1172/JCI118703)
240. Wainwright P & Byrne CD. 2016. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. International Journal of Molecular Sciences 17:367. (doi:10.3390/ijms17030367)
241. Wang H, Zhao M, Sud N, Christian P, Shen J, Song Y, Pashaj A, Zhang K, Carr T & Su Q. 2016. Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis. Scientific Reports 6:32246. (doi:10.1038/srep32246)
242. Wang L, Zhang B, Huang F, Liu B & Xie Y. 2016. Curcumin inhibits lipolysis via suppression of ER stress in adipose tissue and prevents hepatic insulin resistance. Journal of Lipid Research 57:1243-1255. (doi:10.1194/jlr.M067397)
243. Wang Y, Jones Voy B, Urs S, Kim S, Soltani-Bejnood M, Quigley N, Heo YR, Standridge M, Andersen B, Dhar M, et al. 2004. The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. Journal of Nutrition 134:1032-1038
244. Wang Y, Yan C, Liu L, Wang W, Du H, Fan W, Lutfy K, Jiang M, Friedman TC & Liu Y. 2015. 11beta-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue. American Journal of Physiology: Endocrinology and Metabolism 308:E84-E95. (doi:10.1152/ajpendo.00205.2014)
245. Ward KD, Sparrow D, Landsberg L, Young JB, Vokonas PS & Weiss ST. 1996. Influence of insulin, sympathetic nervous system activity, and obesity on blood pressure: the Normative Aging Study. Journal of Hypertension 14:301-308. (doi:10.1097/00004872-199603000-00005)
246. Watt MJ, Holmes AG, Pinnamaneni SK, Garnham AP, Steinberg GR, Kemp BE & Febbraio MA. 2006. Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. American Journal of Physiology: Endocrinology and Metabolism 290:E500-508. (doi:10.1152/ajpendo.00361.2005)
247. Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M & Weiss EJ. 2016. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology 157:570-585. (doi:10.1210/en.2015-1866)
248. Witters LA, Watts TD, Daniels DL & Evans JL. 1988. Insulin stimulates the dephosphorylation and activation of acetyl-CoA carboxylase. PNAS 85:5473-5477. (doi:10.1073/pnas.85.15.5473)
249. Wolfrum C, Borrmann CM, Borchers T & Spener F. 2001. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha-and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. PNAS 98:2323-2328. (doi:10.1073/pnas.051619898)
250. Wu C, Jia Y, Lee JH, Kim Y, Sekharan S, Batista VS & Lee SJ. 2015. Activation of OR1A1 suppresses PPAR-gamma expression by inducing HES-1 in cultured hepatocytes. International Journal of Biochemistry & Cell Biology 64:75-80. (doi:10.1016/j.biocel.2015.03.008)
251. Wu YL, Peng XE, Zhu YB, Yan XL, Chen WN & Lin X. 2016. Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. Journal of Virology 90:1729-1740. (doi:10.1128/JVI.02604-15)
252. Xu C, He J, Jiang H, Zu L, Zhai W, Pu S & Xu G. 2009. Direct effect of glucocorticoids on lipolysis in adipocytes. Molecular Endocrinology 23:1161-1170. (doi:10.1210/me.2008-0464)
253. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, et al. 1999. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Molecular Cell 3:397-403. (doi:10.1016/S1097-2765(00)80467-0)
254. Xu J, Donepudi AC, Moscovitz JE & Slitt AL. 2013. Keap1-knockdown decreases fasting-induced fatty liver via altered lipid metabolism and decreased fatty acid mobilization from adipose tissue. PLoS One 8:e79841. (doi:10.1371/journal.pone.0079841)
255. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, et al. 2009. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259. (doi:10.2337/db08-0392)
256. Xu J, Xiao G, Trujillo C, Chang V, Blanco L, Joseph SB, Bassilian S, Saad MF, Tontonoz P, Lee WN, et al. 2002. Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. Journal of Biological Chemistry 277:50237-50244. (doi:10.1074/jbc.M201208200)
257. Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, Ding X & Li Y. 2012. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One 7:e44136. (doi:10.1371/journal.pone.0044136)
258. Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y, Sekiya M, Tomita S, Okazaki H, Tamura Y, et al. 2005. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. European Journal of Cancer 41:1316-1322. (doi:10.1016/j.ejca.2004.12.037)
259. Yamada T, Zhang SJ, Westerblad H & Katz A. 2010. (beta)-Hydroxybutyrate inhibits insulin-mediated glucose transport in mouse oxidative muscle. American Journal of Physiology: Endocrinology and Metabolism 299:E364-373. (doi:10.1152/ajpendo.00142.2010)
260. Yamauchi T, Iwai M, Kobayashi N & Shimazu T. 1998. Noradrenaline and ATP decrease the secretion of triglyceride and apoprotein B from perfused rat liver. Pflügers Archiv 435:368-374. (doi:10.1007/s004240050525)
261. Yki-Jarvinen H. 2016. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia 59:1104-1111. (doi:10.1007/s00125-016-3944-1)
262. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, et al. 2001. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:131-138. (doi:10.1038/35093050)
263. You M, Matsumoto M, Pacold CM, Cho WK & Crabb DW. 2004. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127:1798-1808. (doi:10.1053/j.gastro.2004.09.049)
264. Yu XX, Lewin DA, Forrest W & Adams SH. 2002. Cold elicits the simultaneous induction of fatty acid synthesis and beta-oxidation in murine brown adipose tissue: prediction from differential gene expression and confirmation in vivo. FASEB Journal 16:155-168. (doi:10.1096/fj.01-0568com)
265. Zhang T, Zhao S, Li W, Ma L, Ding M, Li R & Liu Y. 2014. High-fat diet from perilla oil induces insulin resistance despite lower serum lipids and increases hepatic fatty acid oxidation in rats. Lipids in Health and Disease 13:15. (doi:10.1186/1476-511X-13-15)
266. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, et al. 2006. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. Journal of Biological Chemistry 281:10105-10117. (doi:10.1074/jbc.M600272200)
267. Zhang W, Sun Q, Zhong W, Sun X & Zhou Z. 2016. Hepatic peroxisome proliferator-activated receptor gamma signaling contributes to alcohol-induced hepatic steatosis and inflammation in mice. Alcoholism Clinical and Experimental Research Journal 40:988-999. (doi:10.1111/acer.13049)
268. Zhao Z, Lee YJ, Kim SK, Kim HJ, Shim WS, Ahn CW, Lee HC, Cha BS & Ma ZA. 2009. Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life Sciences 84:688-695. (doi:10.1016/j. lfs.2009.02.021)
269. Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH & Li YM. 2015. Prevalence of nonalcoholic fatty liver disease and economy. Digestive Diseases and Sciences 60:3194-3202. (doi:10.1007/s10620-015-3728-3)